Get the Stockscreener App
53.31
0.60%
0.32
After Hours:
53.31
Biomarin Pharmaceutical Inc stock is traded at $53.31, with a volume of 1.58M.
It is up +0.60% in the last 24 hours and down -3.63% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$52.99
Open:
$53.05
24h Volume:
1.58M
Relative Volume:
0.61
Market Cap:
$10.24B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
19.82
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-0.17%
1M Performance:
-3.63%
6M Performance:
-6.93%
1Y Performance:
-19.54%
1-Day Range:
$52.58
$53.33
1-Week Range:
$52.55
$54.33
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.31 | 10.18B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boone Capital Management LLC Has $24.60 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
AQR Capital Management LLC Acquires 2,654,768 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Camber Capital Management LP Has $32.98 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story - Sahm
Leerink cuts BioMarin Pharmaceutical Inc. (BMRN) price target to $60, citing valuation and competitive challenges - MSN
Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges - Yahoo Finance
California Public Employees Retirement System Sells 102,629 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Inozyme Pharma Acquisition Finalized by BioMarin - Ad-hoc-news.de
BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink - Finviz
BioMarin Pharmaceutical Inc. (BMRN) outlook lowered by Leerink - MSN
Arrowstreet Capital Limited Partnership Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
August 2026 Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Jump Financial LLC Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Technical Reactions to BMRN Trends in Macro Strategies - news.stocktradersdaily.com
BioMarin Pharmaceutical Inc. (BMRN): A bull case theory - MSN
Schroder Investment Management Group Trims Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What margin trends mean for BioMarin Pharmaceutical Inc. stockJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Dodge & Cox - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyJuly 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Finviz
BioMarin Loses Hormone Patent In Europe - Law360
BioMarin Pharmaceutical (NASDAQ:BMRN) Lowered to "Market Perform" Rating by Leerink Partners - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to "Hold" at Leerink Partnrs - MarketBeat
Is BioMarin Pharmaceutical Inc. stock undervalued vs historical averagesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - Newser
Can BioMarin Pharmaceutical Inc. (BM8) stock withstand sector downturns2025 Key Lessons & Technical Pattern Based Signals - Newser
Mackenzie Financial Corp Grows Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
2,043,879 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Norges Bank - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform By Investing.com - Investing.com South Africa
Uber To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
BMRN Experiences Downgrade and Price Target Cut by Leerink Partn - GuruFocus
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Sio Capital Management LLC - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform - Investing.com
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 - marketscreener.com
Hsbc Holdings PLC Boosts Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Korea Investment CORP Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
Edgestream Partners L.P. Has $7.12 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Quadrature Capital Ltd Purchases New Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pullback Watch: Is BioMarin Pharmaceutical Inc. stock oversold or undervaluedQuarterly Market Review & Stock Market Timing Techniques - BỘ NỘI VỤ
Icon Advisers Inc. Co. Has $973,000 Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Charles Schwab Investment Management Inc. Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Vinva Investment Management Ltd Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Thornburg Investment Management Inc. Sells 7,417 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Prudential Financial Inc. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Rhumbline Advisers - MarketBeat
Is BioMarin Pharmaceutical Inc. stock oversold or undervaluedJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - BỘ NỘI VỤ
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):